K J M van Nimwegen1, J H Schieving2, M A A P Willemsen3, J A Veltman4, S van der Burg5, G J van der Wilt6, J P C Grutters7. 1. Radboud University Medical Center, Department for Health Evidence, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. Electronic address: Kirsten.vanNimwegen@radboudumc.nl. 2. Radboud University Medical Center, Department of Neurology, Nijmegen, The Netherlands. Electronic address: Jolanda.Schieving@radboudumc.nl. 3. Radboud University Medical Center, Department of Neurology, Nijmegen, The Netherlands. Electronic address: Michel.Willemsen@radboudumc.nl. 4. Radboud University Medical Center, Department of Genetics, Nijmegen, The Netherlands. Electronic address: Joris.Veltman@radboudumc.nl. 5. Radboud University Medical Center, Department of IQ Healthcare, Nijmegen, The Netherlands. Electronic address: Simone.vanderBurg@radboudumc.nl. 6. Radboud University Medical Center, Department for Health Evidence, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. Electronic address: GertJan.vanderWilt@radboudumc.nl. 7. Radboud University Medical Center, Department for Health Evidence, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. Electronic address: Janneke.Grutters@radboudumc.nl.
Abstract
BACKGROUND: The diagnostic trajectory of complex paediatric neurology may be long, burdensome, and expensive while its diagnostic yield is frequently modest. Improvement in this trajectory is desirable and might be achieved by innovations such as whole exome sequencing. In order to explore the consequences of implementing them, it is important to map the current pathway. To that end, this study assessed the healthcare resource use and associated costs in this diagnostic trajectory in the Netherlands. METHODS: Fifty patients presenting with complex paediatric neurological disorders of a suspected genetic origin were included between September 2011 and March 2012. Data on their healthcare resource utilization were collected from the hospital medical charts. Unit prices were obtained from the Dutch Healthcare Authority, the Dutch Healthcare Insurance Board, and the financial administration of the hospital. Bootstrap simulations were performed to determine mean quantities and costs. RESULTS: The mean duration of the diagnostic trajectory was 40 months. A diagnosis was established in 6% of the patients. On average, patients made 16 physician visits, underwent four imaging and two neurophysiologic tests, and had eight genetic and 16 other tests. Mean bootstrapped costs per patient amounted to €12,475, of which 43% was for genetic tests (€5,321) and 25% for hospital visits (€3,112). CONCLUSION: Currently, the diagnostic trajectories of paediatric patients who have complex neurological disease with a strong suspected genetic component are lengthy, resource-intensive, and low-yield. The data from this study provide a backdrop against which the introduction of novel techniques such as whole exome sequencing should be evaluated.
BACKGROUND: The diagnostic trajectory of complex paediatric neurology may be long, burdensome, and expensive while its diagnostic yield is frequently modest. Improvement in this trajectory is desirable and might be achieved by innovations such as whole exome sequencing. In order to explore the consequences of implementing them, it is important to map the current pathway. To that end, this study assessed the healthcare resource use and associated costs in this diagnostic trajectory in the Netherlands. METHODS: Fifty patients presenting with complex paediatric neurological disorders of a suspected genetic origin were included between September 2011 and March 2012. Data on their healthcare resource utilization were collected from the hospital medical charts. Unit prices were obtained from the Dutch Healthcare Authority, the Dutch Healthcare Insurance Board, and the financial administration of the hospital. Bootstrap simulations were performed to determine mean quantities and costs. RESULTS: The mean duration of the diagnostic trajectory was 40 months. A diagnosis was established in 6% of the patients. On average, patients made 16 physician visits, underwent four imaging and two neurophysiologic tests, and had eight genetic and 16 other tests. Mean bootstrapped costs per patient amounted to €12,475, of which 43% was for genetic tests (€5,321) and 25% for hospital visits (€3,112). CONCLUSION: Currently, the diagnostic trajectories of paediatric patients who have complex neurological disease with a strong suspected genetic component are lengthy, resource-intensive, and low-yield. The data from this study provide a backdrop against which the introduction of novel techniques such as whole exome sequencing should be evaluated.
Authors: Terry Vrijenhoek; Eline M Middelburg; Glen R Monroe; Koen L I van Gassen; Joost W Geenen; Anke M Hövels; Nine V Knoers; Hans Kristian Ploos van Amstel; Gerardus W J Frederix Journal: Eur J Hum Genet Date: 2018-06-29 Impact factor: 4.246
Authors: Tiong Yang Tan; Oliver James Dillon; Zornitza Stark; Deborah Schofield; Khurshid Alam; Rupendra Shrestha; Belinda Chong; Dean Phelan; Gemma R Brett; Emma Creed; Anna Jarmolowicz; Patrick Yap; Maie Walsh; Lilian Downie; David J Amor; Ravi Savarirayan; George McGillivray; Alison Yeung; Heidi Peters; Susan J Robertson; Aaron J Robinson; Ivan Macciocca; Simon Sadedin; Katrina Bell; Alicia Oshlack; Peter Georgeson; Natalie Thorne; Clara Gaff; Susan M White Journal: JAMA Pediatr Date: 2017-09-01 Impact factor: 16.193
Authors: Robin Z Hayeems; Jasmin Bhawra; Kate Tsiplova; M Stephen Meyn; Nasim Monfared; Sarah Bowdin; D James Stavropoulos; Christian R Marshall; Raveen Basran; Cheryl Shuman; Shinya Ito; Iris Cohn; Courtney Hum; Marta Girdea; Michael Brudno; Ronald D Cohn; Stephen W Scherer; Wendy J Ungar Journal: Eur J Hum Genet Date: 2017-11-20 Impact factor: 4.246
Authors: Xin Niu; Laura M Amendola; Ragan Hart; Caroline S Bennette; Patrick Heagerty; Martha Horike-Pyne; Susan B Trinidad; Elisabeth A Rosenthal; Bryan Comstock; Chris Nefcy; Fuki M Hisama; Robin L Bennett; William M Grady; Carlos J Gallego; Peter Tarczy-Hornoch; Stephanie M Fullerton; Wylie Burke; Dean A Regier; Michael O Dorschner; Brian H Shirts; Peggy D Robertson; Deborah A Nickerson; Donald L Patrick; Gail P Jarvik; David L Veenstra Journal: Contemp Clin Trials Date: 2019-08-07 Impact factor: 2.226
Authors: Jung Hoon Son; Gangcai Xie; Chi Yuan; Lyudmila Ena; Ziran Li; Andrew Goldstein; Lulin Huang; Liwei Wang; Feichen Shen; Hongfang Liu; Karla Mehl; Emily E Groopman; Maddalena Marasa; Krzysztof Kiryluk; Ali G Gharavi; Wendy K Chung; George Hripcsak; Carol Friedman; Chunhua Weng; Kai Wang Journal: Am J Hum Genet Date: 2018-06-28 Impact factor: 11.025
Authors: Niall Davison; Katherine Payne; Martin Eden; Marion McAllister; Stephen A Roberts; Stuart Ingram; Graeme C M Black; Georgina Hall Journal: Genet Med Date: 2017-03-16 Impact factor: 8.822
Authors: Glen R Monroe; Gerardus W Frederix; Sanne M C Savelberg; Tamar I de Vries; Karen J Duran; Jasper J van der Smagt; Paulien A Terhal; Peter M van Hasselt; Hester Y Kroes; Nanda M Verhoeven-Duif; Isaäc J Nijman; Ellen C Carbo; Koen L van Gassen; Nine V Knoers; Anke M Hövels; Mieke M van Haelst; Gepke Visser; Gijs van Haaften Journal: Genet Med Date: 2016-02-04 Impact factor: 8.822